Xarelto (rivaroxaban), a Bayer and Johnson & Johnson Janssen Pharmaceutical product is an oral anticoagulant blood thinner that has been on the market since 2011. Xarelto is extremely popular amongst consumers in the United States due to it’s ability to treat a variety of medical issues. These issues include reducing the risk of blood clots and strokes in people with atrial fibrillation; treating deep vein thrombosis and pulmonary embolism; and also reducing the risk of blood clots in patients who recently have had hip or knee replacement surgery.
Unfortunately, this drug has been linked to an extensive increased risk of internal bleeding. The most dangerous side effect for people who take these medications is uncontrollable bleeding. Unlike other blood thinning drugs, Xarelto does not have an antidote or reversal agent to allow physicians to effectively control bleeding problems that arise. Lawsuits allege the manufacturer of Xarelto failed to provide adequate warnings and communications to the medical community and end line consumers of the increased risk of serious bleeding complications and lack of antidote or reversal agent associated with these drugs.
The case is against the manufacturers of Xarelto – Bayer, Johnson & Johnson and Janssen Pharmaceutical – for failure to adequately warn consumer of these adverse consequences, for failure to bring to market an effective antidote or reversal against to stop bleeding, and for defective dosing instructions.
